Impax Laboratories Receives Final FDA Approval for Generic Adoxa® 150 mg Capsules
February 18 2011 - 9:00AM
Business Wire
Impax Laboratories, Inc. (NASDAQ: IPXL) today announced
that the U.S. Food and Drug Administration (FDA) has granted final
approval of the Company’s Abbreviated New Drug Application for its
generic version of Adoxa® (doxycyline monohydrate, 150 mg
capsules). The Company is preparing for product launch through
Global Pharmaceuticals, Impax’s generic division.
Adoxa® is a tetracycline antibiotic used to treat bacterial
infections. According to Wolters Kluwer Health, U.S. sales of
Adoxa® 150 mg capsules were approximately $25 million in the 12
months ended December 2010.
About Impax Laboratories, Inc.
Impax Laboratories, Inc. is a technology based specialty
pharmaceutical company applying its formulation expertise and drug
delivery technology to the development of controlled-release and
specialty generics in addition to the development of branded
products. Impax markets its generic products through its Global
Pharmaceuticals division and markets its branded products through
the Impax Pharmaceuticals division. Additionally, where
strategically appropriate, Impax has developed marketing
partnerships to fully leverage its technology platform. Impax
Laboratories is headquartered in Hayward, California, and has a
full range of capabilities in its Hayward, Philadelphia and Taiwan
facilities. For more information, please visit the Company's Web
site at: www.impaxlabs.com.
"Safe Harbor" statement under the Private Securities Litigation
Reform Act of 1995:
To the extent any statements made in this news release contain
information that is not historical, these statements are
forward-looking in nature and express the beliefs and expectations
of management. Such statements are based on current expectations
and involve a number of known and unknown risks and uncertainties
that could cause the Company’s future results, performance or
achievements to differ significantly from the results, performance
or achievements expressed or implied by such forward-looking
statements. Such risks and uncertainties include the effect of
current economic conditions on the Company’s industry, business,
financial position, results of operations and market value of its
common stock, the ability to maintain an effective system of
internal control over financial reporting, fluctuations in revenues
and operating income, reductions or loss of business with any
significant customer, the impact of competitive pricing and
products and regulatory actions on the Company’s products, the
ability to sustain profitability and positive cash flows, the
ability to maintain sufficient capital to fund operations, the
ability to successfully develop and commercialize pharmaceutical
products, the uncertainty of patent litigation, consumer acceptance
and demand for new pharmaceutical products, the difficulty of
predicting FDA filings and approvals, the inexperience of the
Company in conducting clinical trials and submitting new drug
applications, reliance on key alliance and collaboration
agreements, the availability of raw materials, the ability to
comply with legal and regulatory requirements governing the
healthcare industry, the regulatory environment, exposure to
product liability claims and other risks described in the Company’s
periodic reports filed with the SEC. Forward-looking statements
speak only as to the date on which they are made, and Impax
undertakes no obligation to update publicly or revise any
forward-looking statement, regardless of whether new information
becomes available, future developments occur or otherwise.
Impax Laboratories, Inc. (delisted) (NASDAQ:IPXL)
Historical Stock Chart
From Jul 2024 to Jul 2024
Impax Laboratories, Inc. (delisted) (NASDAQ:IPXL)
Historical Stock Chart
From Jul 2023 to Jul 2024